Setup, so nobody has to ask: dimerisation · mazdutide · 40 °C.
The empirical answer seems settled. The explanation does not.
If the honest answer is that nobody knows, I would rather hear that than a plausible story.
Why does this happen, and what would falsify the usual explanation?
At 40 °C the question is which route is fastest, not whether dimerisation happens — and the routes do not share an activation energy, so their ranking changes with temperature. 40 °C is 35 kelvin above the 5 °C middle of a 2–8 °C refrigerator. The ten-degree rule of thumb — degradation rate roughly doubling per 10 K — makes that about 11 times the refrigerated rate, which is an order-of-magnitude statement and not a shelf life. That multiplier is an average over every route at once, which is exactly why it cannot tell you which one wins. Two chains join, usually through a disulfide, so the product is roughly twice the mass and shows up as a late peak — or as nothing, if it never comes off the column. So the way to answer it for your vial is to pick the method that sees dimerisation specifically and run it against a control held cold, rather than to infer a mechanism from a purity number that averages all of them.
The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.
Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.
Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.
Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.
Swirl, never shake. Aggregation is a handling problem more than a time problem.
edited 26 May 2025 by fiadh_cronin — expanded the table to cover the lower concentration
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.
Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.
A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.
Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.
A mass spectrum names the pathway. Plus one, plus sixteen, minus eighteen.
This is answerable from the chemistry rather than from anecdote, which is unusual and welcome.
Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.
Mechanically, adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.
At dilute concentrations, suspect adsorption before you suspect chemistry.
Worth being precise here: asparagine and glutamine are the deamidation risk, and methionine is the oxidation risk.
Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.
Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.
Cold, dry, dark, still. Those four words cover most of the mitigation.
Start with the sequence, because which pathways are available depends on which residues are present.
Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.
The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.
Sequence decides which pathways are even available. Check the residues.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.